New antibody DM919 takes on advanced cancers in first human trial
NCT ID NCT06328673
First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 25 times
Summary
This early-phase study tests a new drug called DM919, given alone or with another drug (pembrolizumab), in 160 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. Participants receive the drug through an IV and have regular blood tests and scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NEXT Oncology
San Antonio, Texas, 78216, United States
-
The Cancer Institute and Hospital, Chinese Academy of Medical Sciences(CAMS)
Beijing, China
Conditions
Explore the condition pages connected to this study.